{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:17:21Z","timestamp":1782307041579,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["LONG19F5-CI, LONG21R3, MCCOY19RO, SINGH15RO, MANICO19G0"],"award-info":[{"award-number":["LONG19F5-CI, LONG21R3, MCCOY19RO, SINGH15RO, MANICO19G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL144656, HL136786, AI146141, HL167956"],"award-info":[{"award-number":["HL144656, HL136786, AI146141, HL167956"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Chronic pulmonary bacterial infections and associated inflammation remain a cause of morbidity and mortality in people with cystic fibrosis (PwCF) despite new modulator therapies. Therapies targeting host factors that dampen detrimental inflammation without suppressing immune responses critical for controlling infections remain limited, while the development of lung infections caused by antimicrobial resistant bacteria is an increasing global problem, and a significant challenge in CF. Pharmacological compounds targeting the mammalian MAPK proteins MEK1 and MEK2, referred to as MEK1\/2 inhibitor compounds, have potential combined anti-microbial and anti-inflammatory effects. Here we examined the immunomodulatory properties of MEK1\/2 inhibitor compounds PD0325901, trametinib, and CI-1040 on CF innate immune cells. Human CF macrophage and neutrophil phagocytic functions were assessed by quantifying phagocytosis of serum opsonized pHrodo red <jats:italic>E. coli<\/jats:italic>, <jats:italic>Staphylococcus aureus<\/jats:italic>, and zymosan bioparticles. MEK1\/2 inhibitor compounds reduced CF macrophage pro-inflammatory cytokine production without impairing CF macrophage or neutrophil phagocytic abilities. Wild-type C57BL6\/J and <jats:italic>Cftr<\/jats:italic><jats:sup>tm1kth<\/jats:sup> (F508del homozygous) mice were used to evaluate the <jats:italic>in vivo<\/jats:italic> therapeutic potential of PD0325901 compared to vehicle treatment in an intranasal methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) infection with the community-acquired MRSA strain USA300. In both wild-type and CF mice, PD0325901 reduced inflammation associated body mass loss. Wild-type mice treated with PD0325901 had significant reduction in neutrophil-mediated inflammation compared to vehicle treatment groups, with preserved clearance of bacteria in lung, liver, or spleen 1 day after infection in either wild-type or CF mouse models. In summary, this study provides the first data evaluating the therapeutic potential of MEK1\/2 inhibitor to modulate CF immune cells and demonstrates that MEK1\/2 inhibitors diminish pro-inflammatory responses without impairing host defense mechanisms required for acute pathogen clearance.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1275940","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T04:21:49Z","timestamp":1706588509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["MEK1\/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection"],"prefix":"10.3389","volume":"14","author":[{"given":"Mithu","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Serpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryn","family":"Zuiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Hisert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Conrad","family":"Liles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Manicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Hemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"L81","DOI":"10.1152\/ajplung.00051.2010","article-title":"MAPK signaling pathways regulate IL-8 mRNA stability and IL-8 protein expression in cystic fibrosis lung epithelial cell lines","volume":"300","author":"Bhattacharyya","year":"2011","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00237-22","article-title":"Acute infection with a tobramycin-induced small colony variant of staphylococcus aureus causes increased inflammation in the cystic fibrosis rat lung","volume":"90","author":"Bollar","year":"2022","journal-title":"Infect. Immun."},{"key":"B3","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.1038\/s41598-018-27445-7","article-title":"Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound","volume":"8","author":"Bruchhagen","year":"2018","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1165\/rcmb.2008-0170OC","article-title":"Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-\/- mice","volume":"40","author":"Bruscia","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/toxsci\/kfr310","article-title":"An NF-kappaB-independent and Erk1\/2-dependent mechanism controls CXCL8\/IL-8 responses of airway epithelial cells to cadmium","volume":"125","author":"Cormet-Boyaka","year":"2012","journal-title":"Toxicol. Sci."},{"key":"B6","volume-title":"2021 Annual data report","year":"2022"},{"key":"B7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcf.2013.10.007","article-title":"BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs","volume":"13","author":"Doring","year":"2014","journal-title":"J. Cyst Fibros"},{"key":"B8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antiviral Res."},{"key":"B9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4049\/jimmunol.1901171","article-title":"Bone marrow transplantation rescues monocyte recruitment defect and improves cystic fibrosis in mice","volume":"208","author":"Fan","year":"2022","journal-title":"J. Immunol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jaci.2018.10.046","article-title":"Transcriptional and functional diversity of human macrophage repolarization","volume":"143","author":"Gharib","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00323-20","article-title":"Toll-like receptor 2-tpl2-dependent ERK signaling drives inverse interleukin 12 regulation in dendritic cells and macrophages","volume":"89","author":"Groft","year":"2020","journal-title":"Infect. Immun."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2006-0184TR","article-title":"Cystic fibrosis mouse models","volume":"36","author":"Guilbault","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41564-020-0756-3","article-title":"Lactate production by Staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection","volume":"5","author":"Heim","year":"2020","journal-title":"Nat. Microbiol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"2101032","DOI":"10.1183\/13993003.01032-2021","article-title":"Static mucus impairs bacterial clearance and allows chronic infection with Pseudomonas aeruginosa in the cystic fibrosis rat","volume":"60","author":"Henderson","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B15","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jleuko\/qiad033","article-title":"Neutrophil defect and lung pathogen selection in cystic fibrosis","volume":"113","author":"Jennings","year":"2023","journal-title":"J. Leukoc. Biol."},{"key":"B17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/thoraxjnl-2021-217576","article-title":"Bacterial biofilms predominate in both acute and chronic human lung infections","volume":"77","author":"Kolpen","year":"2022","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J. Cyst Fibros"},{"key":"B19","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2147\/COPD.S211619","article-title":"Dual role for A MEK inhibitor as A modulator of inflammation and host defense mechanisms with potential therapeutic application in COPD","volume":"14","author":"Kurian","year":"2019","journal-title":"Int. J. Chron Obstruct Pulmon Dis."},{"key":"B20","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.1601018","article-title":"IL-10 Plays Opposing Roles during Staphylococcus aureus Systemic and Localized Infections","volume":"198","author":"Leech","year":"2017","journal-title":"J. Immunol."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00883-16","article-title":"Staphylococcus aureus survives in cystic fibrosis macrophages, forming a reservoir for chronic pneumonia","volume":"85","author":"Li","year":"2017","journal-title":"Infect. Immun."},{"key":"B22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.4049\/jimmunol.1601059","article-title":"MEK1\/2 inhibition promotes macrophage reparative properties","volume":"198","author":"Long","year":"2017","journal-title":"J. Immunol."},{"key":"B23","first-page":"13","article-title":"Pharmacologic inhibition of MEK1\/2 reduces lung inflammation without impairing bacterial clearance in experimental","volume":"9","author":"Long","year":"2017","journal-title":"Pseudomonas aeruginosa pneumonia. Pneumonia (Nathan)"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132377","article-title":"MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury","volume":"4","author":"Long","year":"2019","journal-title":"JCI Insight"},{"key":"B25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-62703-845-4_2","article-title":"Isolation of human neutrophils from venous blood","volume":"1124","author":"Nauseef","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"B26","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1128\/AAC.00968-15","article-title":"Role of interleukin-12 in protection against pulmonary infection with methicillin-resistant Staphylococcus aureus","volume":"59","author":"Nguyen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"crossref","first-page":"111797","DOI":"10.1016\/j.celrep.2022.111797","article-title":"Recruited monocytes\/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis","volume":"41","author":"Oz","year":"2022","journal-title":"Cell Rep."},{"key":"B28","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: An update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr. Pulmonol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201708-1616OC","article-title":"Infection is not required for mucoinflammatory lung disease in CFTR-knockout ferrets","volume":"197","author":"Rosen","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B30","doi-asserted-by":"crossref","first-page":"106552","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B31","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s10096-016-2754-1","article-title":"Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit","volume":"35","author":"Saint","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B32","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/pharmaceutics14091776","article-title":"The MEK1\/2 inhibitor ATR-002 (Zapnometinib) synergistically potentiates the antiviral effect of direct-acting anti-SARS-coV-2 drugs","volume":"14","author":"Schreiber","year":"2022","journal-title":"Pharmaceutics"},{"key":"B33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00018-021-04085-1","article-title":"The MEK1\/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine\/chemokine responses","volume":"79","author":"Schreiber","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"B34","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.bcp.2009.03.012","article-title":"Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury","volume":"77","author":"Schuh","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.202004-0991OC","article-title":"Single-cell transcriptional archetypes of airway inflammation in cystic fibrosis","volume":"202","author":"Schupp","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B36","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2015.01.160","article-title":"Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-alpha production and endotoxin shock","volume":"458","author":"Shi-Lin","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B38","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1097\/CCM.0000000000001672","article-title":"Delayed mitogen-activated protein kinase\/extracellular signal-regulated kinase inhibition by trametinib attenuates systemic inflammatory responses and multiple organ injury in murine sepsis","volume":"44","author":"Smith","year":"2016","journal-title":"Crit. Care Med."},{"key":"B39","doi-asserted-by":"crossref","first-page":"e22270","DOI":"10.1096\/fj.202100458RRR","article-title":"Targeting the EGFR-ERK axis using the compatible solute ectoine to stabilize CFTR mutant F508del","volume":"36","author":"Wellmerling","year":"2022","journal-title":"FASEB J."},{"key":"B40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/cid\/cit270","article-title":"Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis","volume":"57","author":"Wolter","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.bbagen.2015.02.004","article-title":"Cigarette smoke exposure reveals a novel role for the MEK\/ERK1\/2 MAPK pathway in regulation of CFTR","volume":"1850","author":"Xu","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B42","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jbmr.4570","article-title":"Enhancement of impaired MRSA-infected fracture healing by combinatorial antibiotics and modulation of sustained inflammation","volume":"37","author":"Yu","year":"2022","journal-title":"J. Bone Miner Res."},{"key":"B43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat.\u00a0Rev. Clin. Oncol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1275940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T04:22:13Z","timestamp":1706588533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1275940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":43,"alternative-id":["10.3389\/fcimb.2024.1275940"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1275940","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"article-number":"1275940"}}